Overview

Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation

Status:
Not yet recruiting

Trial end date:
2027-12-31

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of low-dose versus standard-dose rivaroxaban anticoagulation therapy in elderly patients with atrial fibrillation.

Phase:

Phase 4

Details

Lead Sponsor:

China National Center for Cardiovascular Diseases

Treatments:

Rivaroxaban